Cleerly® Unveils Innovative Cleerly® ISCHEMIA™ Solution for Analyzing Heart Disease
Wednesday, January 10, 2024
Cleerly, a company at the forefront of transforming diagnostic standards for heart disease, has launched Cleerly ISCHEMIA, a cutting-edge analysis software that recently obtained FDA 510(k) medical device clearance. This innovative tool, utilizing automated machine learning for diagnostic support, is intended to assist patients undergoing coronary computed tomography angiography (CCTA) analysis with Cleerly Labs software.
By employing AI capabilities, Cleerly ISCHEMIA assesses the probability of coronary vessel ischemia through quantitative measures of atherosclerosis, stenosis, and vascular morphology derived from CCTA images.
The software offers personalized analysis when used by healthcare providers. Cleerly ISCHEMIA is grounded in more than two decades of scientific research from landmark trials such as CREDENCE and PACIFIC, exemplifying Cleerly's commitment to research-backed solutions and scientific innovation.